Navigation Links
Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntington's Disease
Date:7/3/2008

SAN FRANCISCO, July 3 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will hold a teleconference at 5:00 p.m. EDT on Monday, July 7, to discuss top-line results from its randomized, double-blind, placebo-controlled Phase 2 clinical trial of dimebon(TM) in Huntington's disease.

Teleconference/Webcast Details

To participate in the live call on Monday, July 7, at 5:00 p.m. Eastern time by telephone, please dial 877-419-6590 from the U.S. or 719-325-4860 internationally. A telephone replay will be available until July 9 at midnight following the conclusion of the call by dialing 888-203-1112 from the U.S. or 719-457-0820 for international callers and entering passcode 4109873. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com. A replay of the webcast will be available on the Company's website for 30 days.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases of the central nervous system and cancers for which there are limited treatment options. Medivation aims to revolutionize the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of dimebon(TM) in Alzheimer's disease, a Phase 2 clinical trial of dimebon in patients with Huntington's disease, and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. For more information, please visit us at

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
2. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
3. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
4. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
5. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
6. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
7. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
8. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
9. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
10. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
11. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...v. 9 Keryx Biopharmaceut...company focused on the acquisition, development an...eutical products for the treatment of life-threate...(the "Company"), today announced its results for t...t September 30, 2009, the Company had cash, cash e...
(Date:11/9/2009)...v. 9 Patent attorneys Cheryl Lilje... J. D., will showcase Stipkala LLC at the Texas Li...will be held at the Institute of Molecular Medicin...ce provides a platform for cutting-edge companies ...rs, and will feature keynote addresses and panel d...
(Date:11/9/2009)...v. 9 MISSION Skincare®, the i...Serena Williams, soccer professional Mia Hamm, and...tive Lifestyle Skincare Destinations" in the beaut...across the country beginning this week. Stocked wi...s, MISSION and CVS/pharmacy have set out to establ...
Breaking Medicine Technology:Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results 4Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results 5Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results 6Glamour Magazine Woman of the Year and MISSION Skincare Co-Founder, Serena Williams, Teams Up with CVS/pharmacy to Launch National 'Active Lifestyle Skincare Destinations' 2Glamour Magazine Woman of the Year and MISSION Skincare Co-Founder, Serena Williams, Teams Up with CVS/pharmacy to Launch National 'Active Lifestyle Skincare Destinations' 3Pelosi Democratic Leaders Remarks Today at News Conference on Legislative Accomplishments 53395 1Pelosi Democratic Leaders Remarks Today at News Conference on Legislative Accomplishments 53395 2Pelosi Democratic Leaders Remarks Today at News Conference on Legislative Accomplishments 53395 3Pelosi Democratic Leaders Remarks Today at News Conference on Legislative Accomplishments 53395 4Pelosi Democratic Leaders Remarks Today at News Conference on Legislative Accomplishments 53395 5Pelosi Democratic Leaders Remarks Today at News Conference on Legislative Accomplishments 53395 6Pelosi Democratic Leaders Remarks Today at News Conference on Legislative Accomplishments 53395 7Pelosi Democratic Leaders Remarks Today at News Conference on Legislative Accomplishments 53395 8Pelosi Democratic Leaders Remarks Today at News Conference on Legislative Accomplishments 53395 9BBV Vietnam S E A Acquisition Corp Announces Signing of Letter of Intent for Business Combination with Migami Inc 53392 1BBV Vietnam S E A Acquisition Corp Announces Signing of Letter of Intent for Business Combination with Migami Inc 53392 2Excaliard Pharmaceuticals Appoints Jay Birnbaum Ph D to the Board of Directors 53389 1Excaliard Pharmaceuticals Appoints Jay Birnbaum Ph D to the Board of Directors 53389 2
...J., March 12 Genta,Incorporated (Nasdaq: GNTA ) ... the quarter and year ended December 31, 2007. The...uding:, -- AGENDA Phase 3 trial using key bio..., G4544, completes initial Phase 1 trial; planned ...oral taxane, becomes new clinical-stage product ...
... FDA Approve Novel Anesthesia Drug to Reverse Musc..., KENILWORTH, N.J., March 11 Schering-Plough,(NY...Drug Administration,(FDA) Advisory Committee on An...dex for approval. After reviewing data on the safe...nanimously recommended approval of the,company,s a...
Other Medicine Technology:Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 2Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 3Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 4Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 5Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 6Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 7Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 8Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 9Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights 10FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent 2FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent 3FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent 4
(Date:11/9/2009)...mood despite similar weight loss , , MON...ow-carbohydrate diet such as the popular Atkins pr... people lose pounds over the course of a year. ,...sult in long-term improvement in mood, according t...rnal Medicine . , People on both diets consumed...
(Date:11/9/2009)...-FirstCall/ - Hard To Treat Diseases (HTDS.PK) ww... a US$41 billion international healthcare company,...artner, Zhejiang Tianyuan Bio-Pharmaceutical Co., ...will begin a five-year, $1 billion China initiativ...rease its investment in its China R&D facility...
(Date:11/9/2009)...ffered in April 2010, Provides First Responders wi...ambridge, MA (Vocus) November 9, 2009 -- When Stef...rst inspected a suspected mass grave at Dasht-e-L...team of experts to help interpret the scene. He kn...rst step in securing evidence of a human rights vi...
(Date:11/9/2009)...swire/ -- Actress Mariska Hargitay and the Joyfu...rday to raise awareness about the need for domesti...by building healing and wellness kits for women in...e one to each of the estimated 600 women currently...tic violence shelters. ,, "Our goal is to shine...
(Date:11/9/2009)...hlighting a commitment to providing long-term heal...d digital display technology options, LG Electroni...pital Grade LCD HDTVs this week at the Association...eeting and exposition (booth #1760). ,, On disp..." Long-Term Care LCD HDTVs bring a sense of home a...
Breaking Medicine News(10 mins):Health News:To Feel Better, Low-Fat Diet May Be Best 2Health News:To Feel Better, Low-Fat Diet May Be Best 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 4Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 2Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 3Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 4Health News:Actress Mariska Hargitay and the Joyful Heart Foundation Join philosophy to Serve Women in Crisis Throughout Los Angeles County 2Health News:Actress Mariska Hargitay and the Joyful Heart Foundation Join philosophy to Serve Women in Crisis Throughout Los Angeles County 3Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 2Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 3Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 4Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 5
...llowing is an Op-Ed,by David W. Gorman, Washington...ican Veterans:, On Veterans Day, politicians will...action in Iraq and Afghanistan as if this "statist...., That 30,000 number is a fantasy., Here,s the ...
...lth Management With Business Objectives, Watson ...vey Finds, WASHINGTON, Nov. 7 With continuing pr...s plan to offer financial,incentives to reward wor...lth, a non-profit association of 285 large,employe...
...des researchers from the University of Cincinnati ... violence-related deaths in Hamilton County, Ohio,...stic violence over that period, 94 percent of the ...a gunshot wound fired by their spouses. Forty-four...
...rance program, Seguro Popular, which was created t...n uninsured by 2010, is having a positive effect o...ountry, according to a study published in the Octo... treatment for hypertension and significantly more...
...ogists recommends regular hand washing to,decrease...ns, NORTHFIELD, Ill., Nov. 7 ,Methicillin-resista...ig,name that is suddenly causing big problems for ...espond to treatment with,common antibiotics, such ...
...of tumor types, studies find , , WEDNESDAY...1 million British women finds that overweight or o...er cases. , That,s about 6,000 out of the 120,000 ...her risk of developing and dying from cancer, incl...
Other Medicine News:Health News:Shape Shifting on Veterans Day 2Health News:More Employers to Offer Workers Financial Incentives for Healthy Behavior 2Health News:More Employers to Offer Workers Financial Incentives for Healthy Behavior 3Health News:More Employers to Offer Workers Financial Incentives for Healthy Behavior 4Health News:Researchers analyze domestic violence deaths 2Health News:Researchers analyze domestic violence deaths 3Health News:Mexico's expanded health insurance improves hypertension treatment 2Health News:Good Hygiene Is Key to Preventing MRSA 2Health News:Excess Pounds Raise Women's Cancer Risk 2Health News:Excess Pounds Raise Women's Cancer Risk 3
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
Medicine Products: